Canada markets open in 1 hour 10 minutes

Astellas Pharma Inc. (4503.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
1,951.00+0.50 (+0.03%)
At close: 3:15PM JST

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
http://www.astellas.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees15,455

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenji Yasukawa Ph.D.Pres, CEO & Representative Director220MN/A1960
Mr. Naoki Okamura BScExec. VP, CFO, Chief Strategy Officer, Chief Bus. Officer & Representative DirectorN/AN/AN/A
Mr. Yoshitsugu Shitaka Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Fumiaki SakuraiChief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.N/AN/AN/A
Ms. Catherine B. LevittGen. CounselN/AN/AN/A
Mr. Stig OgataVP of Corp. CommunicationsN/AN/AN/A
Ms. Collette TaylorSr. VP of HRN/AN/A1963
Chihiro YokotaSr. Corp. Exec. and Head of Japan/Asia Devel., Devel.N/AN/AN/A
Dr. Charlotte M. E. KremerHead of Medical Affairs & Exec. VPN/AN/AN/A
Mr. Songlin Xue M.D., Ph.D.Head of PharmacovigilanceN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.’s ISS Governance QualityScore as of September 26, 2021 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.